Top

Published in:

01-06-2021 | Obesity | Original Paper

Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis

Author: Hamid Ceylan

Published in: Medical Oncology | Issue 6/2021

Abstract

Obesity, which has become one of the biggest public health problems of the twenty-first century, accompanies many chronic conditions, including cancer. On the other hand, liver cancer, which is known to be associated with obesity, is considered another serious threat to public health. However, the underlying drivers of the development of obesity-associated hepatocellular carcinoma (HCC) remain blurry. The current study attempted to identify the key genes and pathways in the obesity-induced development of HCC using integrated bioinformatics analyses. Obesity and HCC-associated gene expression datasets were downloaded from Gene Expression Omnibus (GEO) and analyzed to identify overlapping differentially expressed genes (DEGs) and hub genes. The prognostic potentials, survival analysis, and expression levels of hub genes were further assessed. Moreover, the correlation between hub genes and the immune cells infiltration was analyzed. The findings of this research revealed that both mRNA and protein expression levels of the four hub genes (IGF1, ACADL, CYP2C9, and G6PD) involved in many important metabolic pathways are remarkably altered in both obese individuals and patients with HCC. The results demonstrated that these dysregulated genes in both obesity and HCC may serve as considerable targets for the prevention and treatment of HCC development in obese individuals.

World Health Organization. Noncommunicable diseases country profiles 2018. Geneva: World Health Organization. 2018. https://www.who.int/nmh/publications/ncd-profiles-2018/en/. Last accessed 29 March 2021.

World Health Organization. Global status report on noncommunicable diseases 2014. World Health Organization. 2014. https://www.who.int/nmh/publications/ncd-status-report-2014/en/. Last accessed 29 March 2021.

Collaboration N C D R F. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390:2627–42. https://doi.org/10.1016/S0140-6736(17)32129-3.CrossRef

Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol. 2019;18:810–5. https://doi.org/10.1016/j.aohep.2019.07.004.CrossRefPubMed

Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. https://doi.org/10.4103/jcar.JCar_9_16.CrossRefPubMedPubMedCentral

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76. https://doi.org/10.1053/j.gastro.2007.04.061.CrossRefPubMed

Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53. https://doi.org/10.2147/JHC.S61146.CrossRefPubMedPubMedCentral

Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147–56. https://doi.org/10.1056/NEJMra1011170.CrossRefPubMed

Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16:3603–15. https://doi.org/10.3748/wjg.v16.i29.3603.CrossRefPubMedPubMedCentral

10.

Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56:704–13. https://doi.org/10.1016/j.jhep.2011.09.020.CrossRefPubMed

11.

Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–8. https://doi.org/10.1038/sj.bjc.6603932.CrossRefPubMedPubMedCentral

12.

Katanoda K, Matsuda T. Five-year relative survival rate of liver cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2014;44:302–3. https://doi.org/10.1093/jjco/hyu025.CrossRefPubMed

13.

Zhang C, Peng L, Zhang Y, et al. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. Med Oncol. 2017;34:101. https://doi.org/10.1007/s12032-017-0963-9.CrossRefPubMedPubMedCentral

14.

Lvovs D, Favorova OO, Favorov AV. A polygenic approach to the study of polygenic diseases. Acta Naturae. 2012;4:59–71. https://doi.org/10.32607/20758251-2012-4-3-59-71.CrossRefPubMedPubMedCentral

15.

Li J, Zheng L, Uchiyama A, et al. A data mining paradigm for identifying key factors in biological processes using gene expression data. Sci Rep. 2018;8:9083. https://doi.org/10.1038/s41598-018-27258-8.CrossRefPubMedPubMedCentral

16.

Pihlajamaki J, Boes T, Kim EY, et al. Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab. 2009;94:3521–9. https://doi.org/10.1210/jc.2009-0212.CrossRefPubMedPubMedCentral

17.

Yuan SX, Wang J, Yang F, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2016;63:499–511. https://doi.org/10.1002/hep.27893.CrossRefPubMed

18.

Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41:D991–5. https://doi.org/10.1093/nar/gks1193.CrossRefPubMed

19.

Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–601. https://doi.org/10.1002/pmic.201400515.CrossRefPubMed

20.

Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52. https://doi.org/10.1093/nar/gku1003.CrossRefPubMed

21.

Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

22.

da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. https://doi.org/10.1038/nprot.2008.211.CrossRef

23.

da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13. https://doi.org/10.1093/nar/gkn923.CrossRef

24.

Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556–60. https://doi.org/10.1093/nar/gkz430.CrossRefPubMedPubMedCentral

25.

Gyorffy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241. https://doi.org/10.1371/journal.pone.0082241.CrossRefPubMedPubMedCentral

26.

Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–58. https://doi.org/10.1016/j.neo.2017.05.002.CrossRefPubMedPubMedCentral

27.

Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108–10. https://doi.org/10.1158/0008-5472.CAN-17-0307.CrossRefPubMedPubMedCentral

28.

Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. https://doi.org/10.1126/science.1260419.CrossRefPubMed

29.

Qi Z, Yan F, Chen D, et al. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. 2020. Biosci Rep. https://doi.org/10.1042/BSR20202603.

30.

Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–89. https://doi.org/10.1007/s40273-014-0243-x.CrossRefPubMedPubMedCentral

31.

Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol. 2015;763:64–74. https://doi.org/10.1016/j.ejphar.2015.03.093.CrossRefPubMedPubMedCentral

32.

Mitchell NS, Catenacci VA, Wyatt HR, et al. Obesity: overview of an epidemic. Psychiatr Clin N Am. 2011;34:717–32. https://doi.org/10.1016/j.psc.2011.08.005.CrossRef

33.

Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32:1431–7. https://doi.org/10.1038/ijo.2008.102.CrossRef

34.

World Health Organization. International Agency for Research on Cancer. Cancer fact sheets. Liver cancer. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Last accessed 29 March 2021.

35.

Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97. https://doi.org/10.1016/j.metabol.2018.11.014.CrossRefPubMed

36.

Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–33. https://doi.org/10.1002/hep.29466.CrossRefPubMed

37.

Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–95. https://doi.org/10.1002/hep.26986.CrossRefPubMed

38.

Wrigley S, Arafa D, Tropea D. Insulin-like growth factor 1: at the crossroads of brain development and aging. Front Cell Neurosci. 2017;11:14. https://doi.org/10.3389/fncel.2017.00014.CrossRefPubMedPubMedCentral

39.

Xu GS, Li ZW, Huang ZP, et al. MiR-497-5p inhibits cell proliferation and metastasis in hepatocellular carcinoma by targeting insulin-like growth factor 1. Mol Genet Genomic Med. 2019;7:e00860. https://doi.org/10.1002/mgg3.860.CrossRefPubMedPubMedCentral

40.

D’Alessandro R, Refolo MG, Lippolis C, et al. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1. Cell Oncol (Dordr). 2018;41:283–96. https://doi.org/10.1007/s13402-018-0370-z.CrossRef

41.

Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62. https://doi.org/10.1038/nrc2664.CrossRefPubMed

42.

Enguita-German M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol. 2014;6:716–37. https://doi.org/10.4254/wjh.v6.i10.716.CrossRefPubMedPubMedCentral

43.

Su WW, Lee KT, Yeh YT, et al. Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal. 2010;24:195–200. https://doi.org/10.1002/jcla.20320.CrossRefPubMedPubMedCentral

44.

Liu B, Balkwill A, Reeves G, et al. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010;340:c912. https://doi.org/10.1136/bmj.c912.CrossRefPubMedPubMedCentral

45.

Aleksandrova K, Stelmach-Mardas M, Schlesinger S. Obesity and liver cancer. Recent Results Cancer Res. 2016;208:177–98. https://doi.org/10.1007/978-3-319-42542-9_10.CrossRefPubMed

46.

Clemmons DR. Role of insulin-like growth factor iin maintaining normal glucose homeostasis. Horm Res. 2004;62(Suppl 1):77–82. https://doi.org/10.1159/000080763.CrossRefPubMed

47.

Lagana AS, Vitale SG, Nigro A, et al. Pleiotropic actions of peroxisome proliferator-activated receptors (PPARs) in dysregulated metabolic homeostasis, ınflammation and cancer: current evidence and future perspectives. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17070999.CrossRefPubMedPubMedCentral

48.

Lamichane S, Dahal Lamichane B, Kwon SM. Pivotal roles of peroxisome proliferator-activated receptors (PPARs) and their signal cascade for cellular and whole-body energy homeostasis. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19040949.CrossRefPubMedPubMedCentral

49.

Antonosante A, d’Angelo M, Castelli V, et al. The ınvolvement of PPARs in the peculiar energetic metabolism of tumor cells. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19071907.CrossRefPubMedPubMedCentral

50.

Chang WH, Lai AG. The pan-cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia. Ann N Y Acad Sci. 2019;1448:65–82. https://doi.org/10.1111/nyas.14170.CrossRefPubMed

51.

Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis. 2010;33:469–77. https://doi.org/10.1007/s10545-010-9061-2.CrossRefPubMedPubMedCentral

52.

Xie BX, Zhang H, Wang J, et al. Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl. 2011;32:170–82. https://doi.org/10.2164/jandrol.109.008748.CrossRefPubMed

53.

Hill VK, Ricketts C, Bieche I, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71:2988–99. https://doi.org/10.1158/0008-5472.CAN-10-4026.CrossRefPubMed

54.

Huang D, Li T, Li X, et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep. 2014;8:1930–42. https://doi.org/10.1016/j.celrep.2014.08.028.CrossRefPubMed

55.

Zhao X, Qin W, Jiang Y, et al. ACADL plays a tumor-suppressor role by targeting Hippo/YAP signaling in hepatocellular carcinoma. NPJ Precis Oncol. 2020;4:7. https://doi.org/10.1038/s41698-020-0111-4.CrossRefPubMedPubMedCentral

56.

Yu D, Green B, Marrone A, et al. Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep. 2015;5:8534. https://doi.org/10.1038/srep08534.CrossRefPubMedPubMedCentral

57.

Chan AT, Tranah GJ, Giovannucci EL, et al. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol. 2004;2:704–12. https://doi.org/10.1016/s1542-3565(04)00294-0.CrossRefPubMed

58.

Martinez C, Garcia-Martin E, Ladero JM, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis. 2001;22:1323–6. https://doi.org/10.1093/carcin/22.8.1323.CrossRefPubMed

59.

Louet M, Labbe CM, Fagnen C, et al. Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30. PLoS One. 2018;13:e0197249. https://doi.org/10.1371/journal.pone.0197249.CrossRefPubMedPubMedCentral

60.

Tsunedomi R, Iizuka N, Hamamoto Y, et al. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol. 2005;27:661–7.PubMed

61.

Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA. 2001;98:15089–94. https://doi.org/10.1073/pnas.241522398.CrossRefPubMedPubMedCentral

62.

Hu DG, Marri S, McKinnon RA, et al. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma. J Pharmacol Exp Ther. 2019;368:363–81. https://doi.org/10.1124/jpet.118.255018.CrossRefPubMed

63.

Shen J, Wang S, Zhang YJ, et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 2012;55:1799–808. https://doi.org/10.1002/hep.25569.CrossRefPubMed

64.

Nogueira V, Hay N. Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 2013;19:4309–14. https://doi.org/10.1158/1078-0432.CCR-12-1424.CrossRefPubMedPubMedCentral

65.

Ozaslan MS, Balci N, Demir Y, et al. Inhibition effects of some antidepressant drugs on pentose phosphate pathway enzymes. Environ Toxicol Pharmacol. 2019;72:103244. https://doi.org/10.1016/j.etap.2019.103244.CrossRefPubMed

66.

Caliskan B, Ozturk Kesebir A, Demir Y, et al. The effect of brimonidine and proparacaine on metabolic enzymes: glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase. Biotechnol Appl Biochem. 2021. https://doi.org/10.1002/bab.2107.CrossRefPubMed

67.

Alfarouk KO, Ahmed SBM, Elliott RL, et al. The pentose phosphate pathway dynamics in cancer and ıts dependency on ıntracellular pH. Metabolites. 2020. https://doi.org/10.3390/metabo10070285.CrossRefPubMedPubMedCentral

68.

Kowalik MA, Columbano A, Perra A. Emerging role of the pentose phosphate pathway in hepatocellular carcinoma. Front Oncol. 2017;7:87. https://doi.org/10.3389/fonc.2017.00087.CrossRefPubMedPubMedCentral

69.

Demir Y, Turkes C, Beydemir S. Molecular docking studies and inhibition properties of some antineoplastic agents against paraoxonase-I. Anticancer Agents Med Chem. 2020;20:887–96. https://doi.org/10.2174/1871520620666200218110645.CrossRefPubMed

70.

Demir Y. The behaviour of some antihypertension drugs on human serum paraoxonase-1: an important protector enzyme against atherosclerosis. J Pharm Pharmacol. 2019;71:1576–83. https://doi.org/10.1111/jphp.13144.CrossRefPubMed

71.

Demir Y. Naphthoquinones, benzoquinones, and anthraquinones: molecular docking, ADME and inhibition studies on human serum paraoxonase-1 associated with cardiovascular diseases. Drug Dev Res. 2020;81:628–36. https://doi.org/10.1002/ddr.21667.CrossRefPubMed

72.

Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39:347–54. https://doi.org/10.1016/j.tibs.2014.06.005.CrossRefPubMedPubMedCentral

73.

Gonul Baltaci N, Guler C, Ceylan H, et al. In vitro and in vivo effects of iron on the expression and activity of glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase in rat spleen. J Biochem Mol Toxicol. 2018. https://doi.org/10.1002/jbt.22229.CrossRefPubMed

74.

Kocpinar EF, Gonul Baltaci N, Ceylan H, et al. Effect of a prolonged dietary iron intake on the gene expression and activity of the testicular antioxidant defense system in rats. Biol Trace Elem Res. 2020;195:135–41. https://doi.org/10.1007/s12011-019-01817-0.CrossRefPubMed

75.

Ma X, Wang L, Huang D, et al. Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway. Nat Commun. 2017;8:1506. https://doi.org/10.1038/s41467-017-01647-5.CrossRefPubMedPubMedCentral

76.

Ye H, Huang H, Cao F, et al. HSPB1 enhances SIRT2-mediated G6PD activation and promotes glioma cell proliferation. PLoS One. 2016;11:e0164285. https://doi.org/10.1371/journal.pone.0164285.CrossRefPubMedPubMedCentral

77.

Debeb BG, Lacerda L, Larson R, et al. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016;7:28329–39. https://doi.org/10.18632/oncotarget.8631.CrossRefPubMedPubMedCentral

78.

Ham M, Lee JW, Choi AH, et al. Macrophage glucose-6-phosphate dehydrogenase stimulates proinflammatory responses with oxidative stress. Mol Cell Biol. 2013;33:2425–35. https://doi.org/10.1128/MCB.01260-12.CrossRefPubMedPubMedCentral

Title: Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis
Author: Hamid Ceylan
Publication date: 01-06-2021
Publisher: Springer US
Keywords: Obesity
Obesity
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Medical Oncology / Issue 6/2021
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01510-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors

H2O2 enhances the anticancer activity of TMPyP4 by ROS-mediated mitochondrial dysfunction and DNA damage

The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients

Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition

Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance

CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page